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Bacterial nitroreductases are members of a diverse family of oxidoreductase enzymes that can catalyse the 
bioreductive activation of nitroaromatic compounds, including anti-cancer and antibiotic prodrugs. 
Nitroreductases have diverse applications in medicine and research, including anti-cancer gene therapy and 
targeted ablation of nitroreductase-expressing cells in transgenic zebrafish to model degenerative diseases. 
Research in these fields to date has focused almost exclusively on the canonical nitroreductase NfsB from 
Escherichia coli (NfsB_Ec), which is a relatively inefficient choice for most applications. By exploring alternative 
nitroreductase candidates from a variety of bacterial species, in concert with enzyme engineering to fine-tune 
specific activities, we have generated improved prodrug-activating enzymes. The nitroreductase NfsB from 
Vibrio vulnificus (NfsB_Vv) has been central to our efforts, and following solution of its crystal structure, was 
selected as a scaffold for directed evolution via site-saturation mutagenesis. By applying library screening 
strategies that involved rounds of both positive and negative selection, several mutants that displayed improved 
activity with a promising next-generation cancer prodrug were identified. In parallel work, an engineered 
NfsB_Vv variant from the same library was found to be substantially improved in activation of the antibiotic 
prodrug metronidazole, which is widely used for targeted cell ablation in transgenic zebrafish. Current methods 
of ablation employing NfsB_Ec require high, near lethal concentrations of metronidazole to achieve total ablation 
of nitroreductase-expressing cells. A transgenic zebrafish line expressing a lead NfsB_Vv variant was generated 
and we found we could achieve robust ablation of nitroreductase-expressing cells at a 100-fold reduced 
metronidazole concentration compared to the NfsB_Ec line (0.1 mM challenge for 24 hours vs 10 mM challenge 
for 48 hours respectively). The identification of these superior nitroreductase variants offers improved tools for 
researchers aiming to achieve targeted cell ablation in either a cancer therapy or degenerative disease-
modelling context. 
 
 
